ArticleFrontiers in pediatrics2025
The heterozygous mutation
Article in Frontiers in pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alport syndrome is an inherited glomerular disease that leads to progressive kidney failure, hearing loss, and eye problems. Diagnosis mostly relies on tests of tissue pathology and genetic analysis. This study aims to clarify the role of the Methods: We collected clinical data from a 12-year-old boy who had "persistent hematuria for 4 years" and performed a renal biopsy, which was pathologically diagnosed as "Alport syndrome". We used high-throughput sequencing technology to conduct whole-exome sequencing (WES) and Sanger sequencing for the patient and his parents. Through bioinformatics analysis, we found that the Results: Our findings show that the COL4A4 c.817-1G > A mutation disrupts mRNA splicing. This mutation affects the splice acceptor site of Intron 13, which is next to Exon 14, causing a 1-bp deletion before Exon 14 and creating a premature stop codon. Consequently, a truncated protein of 273 amino acids is produced, as opposed to the full-length protein of 1,690 amino acids. This finding clarifies the molecular mechanism by which this mutation contributes to Alport syndrome. Conclusion: Our study finds that the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.